Post Reply
101-120 of 256
Q2 Highlights
?
boosted by the consolidation of LMA PacMed Pty Ltd (?LMA PacMed?), acquired in February this
year. Sales in Q2 FY2007 were also US$4.3 million or 18% higher than Q1 FY2007.
Group Net Sales increased by US$3.5 million to US$27.8 million or 14% over Q2 FY2006, partly?
increasing by 10% over Q2 FY2006.
Sales of Laryngeal Masks amounted to US$26.8 million, with sales of single-use devices?
driven by sales of single-use devices as well as sales of the McGrath® Video Laryngoscope.
Despite ongoing aggressive competition, LMA continued to regain lost accounts from
competitors.
Net Sales of Laryngeal Masks in the United States grew 6% to US$15.2 million over Q2 FY2006,?
partly boosted by the consolidation of LMA PacMed. Sales in Germany in Q2 FY2007 were up
11% on the same period last year.
International Net Sales of Laryngeal Masks were up by 16% to US$11.6 million over Q2 FY2006?
reflecting distribution expansion.
Sales of LMA StoneBreakerTM at US$1.0 million were more than double sales in Q1 FY2007,LMA REPORTS DOUBLE DIGIT SALES GROWTH FOR FIRST SIX
MONTHS
Summary of Financial Performance
Three months ended June 30, Six months ended June 30,
(US$?000) 2007
2006
Change
(%)
2007 2006 Change
(%)
Net sales
27,846 24,368 14.3 51,416 44,819 14.7
Gross profit
19,138 17,589 8.8 34,761 32,367 7.4
Operating expenses:
Selling, general and
administrative
(11,925) (9,643) (23,155) (18,868)
Research and development (388) (379) (603) (794)
Amortisation of intangible assets
(161) (14) (220) (28)
Total operating income
6,664 7,553 (11.8) 10,783 12,677 (14.9)
Net income before income
taxes, minority interests and
share of net earnings of
associate
6,934 8,204 (15.5) 11,334 13,386 (15.3)
Income tax expense (770) (741) (1,337) (1,338)
Minority interests (231) 218 (140) 310
Share of net earnings of
associate
- 195 - 168
Net income excluding noncash
stock compensation
charge
5,933 7,876 (24.7) 9,857 12,526 (21.3)
Non-cash stock compensation
charge
(444) (404) (879) (718)
Net income 5,489 7,472 (26.5) 8,978 11,808 (24.0)
Earnings per Share (EPS)
Three months ended June 30, Six months ended June 30,
(U.S. cents)
Before non-cash stock
compensation charge
Diluted EPS, including shares
to be issued for LMA
PacMed
2007 2006 2007 2006(1) 1.021 1.356 1.697 2.156(2) 1.009 1.340 1.677 2.131the point of the IP right is that it protects LMA's invention of a reinforced tip on supraglottic airway devices and it is certainly not about "one should not look at this type of income for bottomline". This means that Ambu would have to stop the sale of the copied product, so LMA would take over the market share i.e more sales for the genuine LMA product.. which means more profits...
I have took advantage of the current depressed market price to buy more LMA lots......
This should give a boost to LMA stock price and profit for this year.
LMA is looking for 3.1 Mil Euro in damages ( 4.2 Mil USD).
18 July 2007
Announcement to the Singapore Exchange
GERMAN PATENT OFFICE UPHOLDS LMA?S IP AGAINST AMBU
CHALLENGE
Mainboard-listed LMA International NV (?LMA?), the global leader in the development
and marketing of the LMA? range of supraglottic airway management devices, is
pleased to announce that the German Patent Office has upheld its intellectual property
right ? German Utility Model DE 299 24 738 ? against a challenge by Danish competitor
Ambu A/S (?Ambu?). This IP right protects LMA?s invention of a reinforced tip on
supraglottic airway devices.
In a separate court action, LMA?s wholly-owned subsidiary, LMA Deutschland GmbH,
had earlier obtained a judgment in Germany that Ambu?s airway devices infringe LMA?s
invention. LMA is seeking ?3.1 million in damages from Ambu for its infringement in
Germany. The decision of the German Patent Office ensures that LMA?s damages claim
action will proceed. That action is currently scheduled to be heard in August 2007.
LMA has additional patent infringement actions pending against Ambu in France and the
Netherlands to protect the same invention and currently has the legal right to commence
similar actions in other markets.
LMA expects Ambu to appeal the German Patent Office?s decision, as it has appealed
the German court?s judgment of infringement.
The link below.
http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_D0EBFA6E5490D58B482573160046399F/$file/LMA_EGM_Notice_110707.pdf?openelement
Enjoy this people....
http://info.sgx.com/webcorannc.nsf/ef3ba6cb188613ea482571b2003641d3/95c0ced517c52caa48257314003a0aea?OpenDocument
opps , here is the upcoming medical conference abstract for the study conducted in singapore:
http://www.asaabstracts.com/strands/asaabstracts/abstract.htm;jsessionid=5F4C2E4AAE511ABC088E032CF1456DB2?year=2007&index=8&absnum=176